Return
Company Page
Amyl Therapeutics
Amyl Therapeutics is a preclinical-stage biotechnology company headquartered at the LegiaPark life sciences campus in Liege, Belgium. Co-founded in November 2020 by Pierre Vandepapeliere and Florent Gros, the company is developing a breakthrough fusion protein platform called ClariTY that targets misfolded amyloid proteins to treat amyloidosis and neurodegenerative diseases such as Alzheimer's and Parkinson's. The company has raised over 27.85 million euros in total funding from investors including Merieux Equity Partners, Noshaq, and the Walloon Region, and is advancing its lead candidate toward clinical development.
Company Founded in 2020
Healthtech & Biotech